Biogen Idec Lifts 2012 View; Quarterly Net Up 13%
Biogen Idec lifts 2012 view; quarterly net up 13%
Filed under: drug treatment news 2012
Biogen Idec Inc.'s (NASDAQ:BIIB) third-quarter earnings rose 13% as the biopharmaceutical company saw growth of its biggest drug, multiple-sclerosis treatment Avonex, and received a boost from a gain tied to Benlysta. For the year, the company raised …
Read more on MarketWatch
Generic Plavix Hurts Bristol-Myers – Analyst Blog
Filed under: drug treatment news 2012
… decreased approximately 33% from the year-ago period. The year-over-year decline in earnings was attributable to the reduced sales of Bristol-Myers/ Sanofi 's ( SNY ) blood-thinner Plavix, which went off-patent in the US on May 17, 2012 …
Read more on NASDAQ
Lilly Profit Misses Estimates as Generic Drugs Cut Sales
Filed under: drug treatment news 2012
By Shannon Pettypiece on October 24, 2012 … (LLY) reported third- quarter earnings that missed analyst estimates after generic competition reduced revenue from the schizophrenia treatment Zyprexa, once the company's top-selling drug. Earnings …
Read more on Businessweek
Stocks To Watch: Big Earnings To Watch Thursday: P&G, Aetna, Apple
First up in another busy day for earnings will be Procter & Gamble, but investors’ attention will hardly flag once the regular session ends in New York: Apple and Amazon are slated to report results after the close. … Read News